INS and Hyperglycemia: During 6 separate study days, GLP-2 (6 pmol/kg/min for 10 minutes and 2 pmol/kg/min for the following 90 minutes) and placebo (saline), respectively, were infused intravenously during insulin-induced hypoglycemia (∼2.5 mmol/L), euglycemia (∼5 mmol/L), or hyperglycemia (∼10 mmol/L).